Serum Neurofilament Light Chain for Multiple Sclerosis Relapses
- 14 May 2024
- journal article
- editorial
- Published by Wolters Kluwer Health in Neurology
- Vol. 102 (9) , e209456
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple SclerosisNeurology, 2024
- Serum Levels of CXCL13 Are Associated With Teriflunomide Response in Patients With Multiple SclerosisNeurology Neuroimmunology & Neuroinflammation, 2022
- Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple SclerosisNeurology Neuroimmunology & Neuroinflammation, 2022
- Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort studyEBioMedicine, 2020
- Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple SclerosisJAMA Neurology, 2020
- Neurofilaments as biomarkers in neurological disordersNature Reviews Neurology, 2018
- Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndromeBrain, 2018
- Monitoring disease activity in multiple sclerosis using serum neurofilament light proteinNeurology, 2017
- Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosisAnnals of Neurology, 2017
- MS disease activity in RESTORENeurology, 2014